Novo Nordisk ousts CEO after falling behind in weight loss market

Novo's shares have plunged since hitting a record-high in June last year as competition, particularly from U.S. rival Eli Lilly (LLY.N), makes inroads into its market share and as its pipeline of new drugs has failed to impress investors.

On the surface, it does seem like Novo Nordisk is afraid to compete on price with Zepbound, even though doctors are recommending Zepbound over Wegovy.
 
Everyone is dying for these meds, I am surprised the manufacturers don't just start their own telehealth services.
It costs almost nothing for the manufacturer to make. If they just were not as greedy as they are, and took this or a similar approach, they would have so many more patients. Patients=$
 

Trending Topics

Latest Posts

Forum Statistics

Threads
3,274
Messages
53,782
Members
6,974
Latest member
swetmo